Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2041–2064 of 5,924 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: mRI Clear all
Recruiting Not applicable Interventional

A Study of the Use of 3D Technology to Guide Head and Neck Surgery

NCT06676592
View directory record Official record
Conditions
Surgery, Head and Neck Disorder
Interventions
Preoperative imaging, 3D framework
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Nov 14, 2026, 11:17 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women

NCT02122198
View directory record Official record
Conditions
Cognitive Impairment, Executive Dysfunction, Endothelial Dysfunction, Cardiovascular Disease
Interventions
Leuprolide acetate, Estradiol, Medroxyprogesterone, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 60 Years · Female only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
Aurora, Colorado • Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Nov 14, 2026, 11:17 AM EST
Recruiting Phase 3 Interventional

Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis

NCT07325292
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Frexalimab, MRI contrast-enhancing preparations
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 60 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
34
States / cities
Cullman, Alabama • Homewood, Alabama • Phoenix, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 14, 2026, 11:17 AM EST
Withdrawn No phase listed Observational

MRI and Bladder Cancer Chemotherapy

NCT01922232
View directory record Official record
Conditions
Invasive Bladder Cancer
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2014 · Synced Nov 14, 2026, 11:17 AM EST
Recruiting Phase 2 Interventional

Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer

NCT06918132
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Cemiplimab, Fianlimab, Magnetic Resonance Imaging, Surgical Procedure, Computed Tomography, Positron Emission Tomography
Procedure · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 14, 2026, 11:17 AM EST
Active, not recruiting Phase 2 Interventional Results available

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

NCT04739800
View directory record Official record
Conditions
Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Clear Cell Adenocarcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Fallopian Tube High Grade Serous Adenocarcinoma, Recurrent Fallopian Tube Mucinous Adenocarcinoma, Recurrent Fallopian Tube Transitional Cell Carcinoma, Recurrent Fallopian Tube Undifferentiated Carcinoma, Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian High Grade Serous Adenocarcinoma, Recurrent Ovarian Low Grade Serous Adenocarcinoma, Recurrent Ovarian Mucinous Adenocarcinoma, Recurrent Ovarian Seromucinous Carcinoma, Recurrent Ovarian Transitional Cell Carcinoma, Recurrent Ovarian Undifferentiated Carcinoma, Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Clear Cell Adenocarcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma, Recurrent Primary Peritoneal Transitional Cell Carcinoma, Recurrent Primary Peritoneal Undifferentiated Carcinoma, Refractory Fallopian Tube Clear Cell Adenocarcinoma, Refractory Fallopian Tube Endometrioid Adenocarcinoma, Refractory Fallopian Tube High Grade Serous Adenocarcinoma, Refractory Fallopian Tube Mucinous Adenocarcinoma, Refractory Fallopian Tube Transitional Cell Carcinoma, Refractory Fallopian Tube Undifferentiated Carcinoma, Refractory Low Grade Fallopian Tube Serous Adenocarcinoma, Refractory Ovarian Clear Cell Adenocarcinoma, Refractory Ovarian Endometrioid Adenocarcinoma, Refractory Ovarian High Grade Serous Adenocarcinoma, Refractory Ovarian Low Grade Serous Adenocarcinoma, Refractory Ovarian Mucinous Adenocarcinoma, Refractory Ovarian Seromucinous Carcinoma, Refractory Ovarian Transitional Cell Carcinoma, Refractory Ovarian Undifferentiated Carcinoma, Refractory Primary Peritoneal Clear Cell Adenocarcinoma, Refractory Primary Peritoneal Endometrioid Adenocarcinoma, Refractory Primary Peritoneal High Grade Serous Adenocarcinoma, Refractory Primary Peritoneal Low Grade Serous Adenocarcinoma, Refractory Primary Peritoneal Transitional Cell Carcinoma, Refractory Primary Peritoneal Undifferentiated Carcinoma
Interventions
Biospecimen Collection, Cediranib Maleate, Computed Tomography, Computed Tomography with Contrast, Durvalumab, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan Hydrochloride
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
384
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Goodyear, Arizona + 288 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2026 · Synced Nov 14, 2026, 11:17 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Relation of Consummatory & Anticipatory Food Reward to Obesity

NCT02084836
View directory record Official record
Conditions
Obesity
Interventions
Functional Magnetic Resonance Imaging
Other
Lead sponsor
Oregon Research Institute
Other
Eligibility
14 Years to 17 Years
Enrollment
162 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Nov 14, 2026, 11:17 AM EST
Active, not recruiting Phase 3 Interventional

Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study

NCT02997228
View directory record Official record
Conditions
Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7
Interventions
Atezolizumab, Bevacizumab, Biospecimen Collection, Computed Tomography, Fluorouracil, Leucovorin, Magnetic Resonance Imaging, Oxaliplatin, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration
Drug · Biological · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
445
States / cities
Kingman, Arizona • Jonesboro, Arkansas • Anaheim, California + 346 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2026 · Synced Nov 14, 2026, 11:17 AM EST
Completed No phase listed Observational

Improving Clinical Staging for Muscle Invasive Bladder Cancer Through Molecular Profiling and Improved Imaging

NCT02203136
View directory record Official record
Conditions
Bladder Cancer
Interventions
Tissue Biopsy, Magnetic Resonance Imaging (MRI)
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2019 · Synced Nov 14, 2026, 11:17 AM EST
No Longer Available No phase listed Expanded access

Clinical Use of 68Ga PSMA-11 PET/CT in Diagnosing, Staging and Restaging Prostate Cancer

NCT05002465
View directory record Official record
Conditions
Prostate Cancer, Prostate Cancer Metastatic, Prostate Cancer Recurrent
Interventions
68Ga-PSMA-11, Positron Emission Tomography/Computed Tomography
Drug · Procedure
Lead sponsor
Dana Mathews
Other
Eligibility
18 Years and older · Male only
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2023 · Synced Nov 14, 2026, 11:17 AM EST
Recruiting Phase 1 Interventional

Safety and Feasibility Study of the CELLSPAN Esophageal Implant (CEI) in Patients Requiring Short Segment Esophageal Replacement

NCT05877300
View directory record Official record
Conditions
Esophageal Diseases
Interventions
CEI Thoracic Surgical Implantation-Cellspan™ Esophageal Implant-Adult (CEI) in patients requiring a full reconstruction of the esophagus, CEI Extra-Thoracic Subdermal Surgical Implantation - Cellspan™ Esophageal Implant-Adult (CEI) in patients that have had a previous partial esophagectomy
Combination Product
Lead sponsor
Harvard Apparatus Regenerative Technology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
3
States / cities
Los Angeles, California • Ann Arbor, Michigan • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Nov 14, 2026, 11:17 AM EST
Recruiting Not applicable Interventional

Neuroplastic Changes Due to an Exercise Intervention That Aid in Lower Limb Recovery After Subcortical Stroke

NCT07663292
View directory record Official record
Conditions
Subcortical Lesions, Stroke
Interventions
HIIT intervention
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Nov 14, 2026, 11:17 AM EST
Active, not recruiting Phase 2 Interventional

CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer

NCT06730100
View directory record Official record
Conditions
Metastatic Mismatch Repair Proficient Colorectal Carcinoma, Refractory Mismatch Repair Proficient Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, pH Low Insertion Peptide-exatecan Conjugate CBX-12, X-Ray Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
15
States / cities
Irvine, California • Los Angeles, California • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 14, 2026, 11:17 AM EST
Completed Not applicable Interventional Results available

Focal Prostate Radio-Frequency Ablation

NCT02328807
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radio-Frequency Ablation (RFA)
Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 6, 2021 · Synced Nov 14, 2026, 11:17 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Improving Functional Outcomes in Patients With Unilateral Vocal Cord Paralysis: Assessment of Adaptation Using Functional Magnetic Resonance Imaging

NCT00597844
View directory record Official record
Conditions
Intrathoracic Malignancies, Unilateral Vocal Cord Paralysis
Interventions
voice evaluation and fMRI, undergo voice evaluation and fMRI prior
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Nov 14, 2026, 11:17 AM EST
Terminated No phase listed Observational Accepts healthy volunteers

DWIBS-MRI: An Adjunct to the Traditional Diagnostic Breast Imaging Evaluation

NCT04491864
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Baylor Research Institute
Other
Eligibility
30 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Nov 14, 2026, 11:17 AM EST
Withdrawn Not applicable Interventional

MRI Adaptive Replanning Using ViewRay

NCT02950792
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
ViewRay MRI, Stereotactic Body Radiation Therapy Boost
Device · Radiation
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 25, 2017 · Synced Nov 14, 2026, 11:17 AM EST
Suspended Not applicable Interventional

Feasibility of OmnEcoil System for Integrated Endorectal MRI and Transrectal MRI-Targeted Biopsy of the Prostate

NCT05362032
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Biopsy, Endorectal Magnetic Resonance Imaging
Device · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
45 Years and older · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Nov 14, 2026, 11:17 AM EST
Completed No phase listed Observational

Hyperbaric Oxygen Treatment in Patients With White Matter Hyperintensities

NCT00497432
View directory record Official record
Conditions
Neurological Impairments, Leukoencephalopathies
Interventions
Not listed
Lead sponsor
St. Luke's Hospital, Chesterfield, Missouri
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Chesterfield, Missouri • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 31, 2013 · Synced Nov 14, 2026, 11:17 AM EST
Completed Phase 1 Interventional Results available

Pharmaco-Magnetic Resonance Spectroscopy (MRS) Study of Clavulanic Acid

NCT04411914
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Clavulanic Acid, Placebo
Drug · Other
Lead sponsor
Temple University
Other
Eligibility
18 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Nov 14, 2026, 11:17 AM EST
Not listed Not applicable Interventional

Dietary Sodium (DS) Intervention to Reduce Volume Overload and Tissue Sodium in Magnetic Resonance Imaging (MRI) for Hemodialysis (HD) Patients

NCT03189758
View directory record Official record
Conditions
Kidney Failure, Chronic, Dietary Modification
Interventions
Observational Control Diet, Controlled Dietary Sodium Restriction
Other
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Nov 14, 2026, 11:17 AM EST
Completed No phase listed Observational Accepts healthy volunteers

DTI of the Brain and Cervical Spine: Evaluation in Normal Subjects and Patients With Cervical Spondylotic Myelopathy

NCT01868958
View directory record Official record
Conditions
Cervical Spondylosis With Myelopathy
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
30 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 15, 2015 · Synced Nov 14, 2026, 11:17 AM EST
Terminated Not applicable Interventional Results available

Optimized Diffusion-Weighted Imaging for the Evaluation of Post-Treatment Squamous Cell Carcinoma in the Neck: Comparative Study With FDG PET/CT

NCT04685798
View directory record Official record
Conditions
Squamous Cell Carcinoma
Interventions
Diffusion-weighted imaging magnetic resonance imaging, FDG PET/CT
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Nov 14, 2026, 11:17 AM EST
Completed No phase listed Observational

MR Assessment of Brain Function Altered by Lead Exposure

NCT00283647
View directory record Official record
Conditions
Lead Exposure
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
19 Years to 26 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Nov 14, 2026, 11:17 AM EST